Please assess the completion status of the following clinical trial:

Trial Title: Pathophysiology of the Upper Airway in Patients With COPD and Concomitant OSA

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for COPD Subjects:~* Age range 40-70 years.~* Demonstrated moderate to severe COPD as determined by spirometry (post-bronchodilator spirometry FEV1/FVC \< 0.70 for diagnosing CODP and FEV1\<80% predicted for staging)~* Smoking history of ≥ 10 pack-years~Inclusion Criteria for Control Subjects~* Age range 40-70 years~* Demonstrated no COPD as determined by normal spirometry (post-bronchodilator spirometry FEV1/FVC \> 0.70 for diagnosing CODP and FEV1\<80% predicted for staging)~* No smoking history as defined by less than 100 cigarettes smoked in a lifetime~Exclusion Criteria for both COPD and Control Subjects:~* Metal objects that may interfere with chest CT quantification including presence of a cardiac pacemaker, defibrillator, metal prosthetic heart valve, metal projectile or metal weapon fragment (bullet, shrapnel, shotgun shot) or metal shoulder prosthesis~* Subjects unable to perform spirometry due to:~  * chest or abdominal surgery in the past three months~ * a heart attack in the last three months~ * detached retina or eye surgery in the past three months~ * hospitalization for any other heart problem in the past month~* History of hypersensitivity to Afrin, Lidocaine or albuterol~* A psychiatric disorder, other than mild depression; e.g. schizophrenia, bipolar disorder, major depression, panic or anxiety disorders.~* More than 10 cups of beverages with caffeine (coffee, tea, soda/pop) per day~* Pregnancy or suspected pregnancy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- COPD Group (Type: ACTIVE_COMPARATOR): Patients who were previously diagnosed of moderate to severe COPD as determined by spirometry. All patients will have sleep and pulmonary physiologic measurements.
- Normal Control Group (Type: ACTIVE_COMPARATOR): Patients who are healthy, without major medical or sleep problems, and have normal spirometry. All patients will have sleep and pulmonary physiologic measurements.

Based on this trial design, predict the completion outcome and termination type (if applicable).